Triple-negative breast cancer symptoms

1
Triple-Negative Breast Cancer Treatment

• About Triple-Negative Breast Cancer (TNBC)
• Triple-negative breast cancer accounts for
  approximately 10 to 15 of all breast cancers.
  The term triple-negative breast cancer (TNBC)
  refers to the fact that the cancer cells dont
  have estrogen
• receptors (ER) or progesterone receptors (PR) and
  also dont create any or excess protein known as
  HER2. (The cells test "negative" on all 3 tests.)
  These cancers tend to be a bit more common in
  women aged less than 40, who are Black, or who
  have a BRCA1 mutation.
• Triple-Negative Breast Cancer differs from other
  kinds of invasive breast cancer in that it tends
  to progress and spread quickly, has limited
  treatment options, and tends to have a poor
  prognosis (outcome).
• Common Characteristics of Triple-Negative Breast
  Cancer Triple-negative breast cancer (TNBC) is
  usually a bit more aggressive, difficult to
  treat, and more likely to recur than cancers that
  are HR-positive or HER2-positive.
• Who Gets Triple-Negative Breast Cancer
• Triple-negative breast cancer (TNBC) is more
  common in
• women aged less than 40
• Black women

2

• women who have a BRCA1 mutation
• Stats As per American Cancer Society,
  triple-negative breast cancer (TNBC) represents
  10 percent of breast cancers overall, but around
  20 percent among Black women, who are affected
  more than any other group.
• Treatments for Triple-Negative Breast Cancer
• Treatments for triple-negative breast cancer may
  include
• surgery
• chemotherapy
• immunotherapy
• radiation therapy
• Newer Treatments for Triple-Negative Breast
  Cancer
• Currently, Keytruda (pembrolizumab) is approved
  by the U.S. FDA for treating unresectable locally
  advanced or metastatic triple-negative,
  PD-L1-positive breast cancer, along with
  chemotherapy. All cancers that are unresectable
  cannot be surgically eliminated.
• The Food and Drug Administration has also
  approved Keytruda along with chemotherapy prior
  to surgery, followed by Keytruda alone after
  surgery for treating early-stage, triple-negative
  breast cancer that has a high probability of
  coming back (recurrence).
• Currently, Trodelvy (sacituzumab govitecan-hziy)
  is approved by the Food and Drug Administration
  for treating previously treated, metastatic
  triple-negative breast cancer (TNBC).
• Trodelvy is supplied for injection 180 mg
  lyophilized powder in single-dose vials for
  reconstitution for intravenous administration.